Impact of race, ethnicity, and social determinants on outcomes following immune checkpoint therapy.

ABSTRACT: Immune checkpoint blockade (ICB) therapies are one of the greatest advances in the history of cancer care and are now commonly used in the management of many different malignancies. However, much remains unknown about the factors that affect the efficacy and side effect profile of these agents. This review delves into the published literature that evaluates the intricate interplay between race, age, gender, and social determinants in shaping outcomes following ICB across solid tumors and hematologic malignancies. We examine the pivotal phase 2 and 3 trials to evaluate the demographics of participants and outcomes based on these variables, if reported. Most, but not all, trials reported some basic demographic information like age, sex, race, ethnicity, and/or geographic area for enrollment.

SUBMITTER: Nayak RK 

PROVIDER: S-EPMC11529590 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature